These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17938988)

  • 41. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
    Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
    Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
    Morris GJ; Mitchell EP
    J Natl Med Assoc; 2007 Jan; 99(1):35-45. PubMed ID: 17304967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
    Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
    BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Should bisphosphonates be used in premenopausal women?
    Cohen A
    Maturitas; 2010 May; 66(1):3-4. PubMed ID: 20356692
    [No Abstract]   [Full Text] [Related]  

  • 48. Patient treatment preferences for osteoporosis.
    Fraenkel L; Gulanski B; Wittink D
    Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
    Tanaka I
    Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe transient osteoporosis of the hip during pregnancy. Successful treatment with intravenous biphosphonates.
    Schapira D; Braun Moscovici Y; Gutierrez G; Nahir AM
    Clin Exp Rheumatol; 2003; 21(1):107-10. PubMed ID: 12673900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates.
    Miller RG; Chretien KC; Meoni LA; Liu YP; Klag MJ; Levine MA
    J Clin Rheumatol; 2005 Feb; 11(1):2-7. PubMed ID: 16357689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy].
    Takeuchi Y
    Clin Calcium; 2012 Jun; 22(6):897-903. PubMed ID: 22653031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 57. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transient osteoporosis associated with pregnancy: use of bisphosphonate in treating a lactating mother.
    Shenker NG; Shaikh MF; Jawad AS
    BMJ Case Rep; 2010 Dec; 2010():. PubMed ID: 22802275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
    Adler RA
    Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison between bisphosphonates and other treatments for osteoporosis.
    Le Goff B; Guillot P; Glémarec J; Berthelot JM; Maugars Y
    Curr Pharm Des; 2010; 16(27):3037-44. PubMed ID: 20722614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.